Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

NCT04431635 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
6
Enrollment
OTHER
Sponsor class

Stopped Loss of study funding

Conditions

Interventions

Sponsor

University of Michigan Rogel Cancer Center

Collaborators